{"chain_id": "chain_000000", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5948914", "num_turns": 4, "model": "gpt-4.1", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5948914, is the following pharmacogenomic claim supported or contradicted: Genotypes GT + TT are not associated with overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.**\n\nIn the context of this paper (PMCID PMC5948914), the only SNPs with a GG/GT/TT genotype pattern among the six tested are SLC29A3 S158F (rs780668, genotypes CC/CT/TT) and possibly others, but the claim refers to a general \"GT + TT\" vs \"GG\" comparison.\n\nFor SLC29A3 S158F (rs780668), the paper reports that the CT/TT genotypes (i.e., carriers of the T allele) are associated with **increased overall survival** compared to the CC genotype (see Table 2 and Results: \"SLC29A3 S158F (c.473C > T, rs780668) was found to be associated with increased OS. Patients with CT/TT genotype were shown to have longer median OS compared to CC genotype... HR 0.49 (95% CI 0.27-0.88), adjusted P = 0.017\").\n\nTherefore, the claim that \"GT + TT are not associated with overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG\" is **contradicted**", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2231142 and gemcitabine in Disease:Non-Small Cell Lung Carcinoma (PMCID PMC5948914), what p-value was reported for this association?", "answer": "= 0.080", "response": "For the association of rs2231142 (ABCG2 Q141K) and gemcitabine in Non-Small Cell Lung Carcinoma, the reported p-value for progression-free survival (PFS) in the multivariate analysis was **0.007** (adjusted p-value). For overall survival (OS), the adjusted p-value was **0.080**. \n\nReference: Table 2, Results section.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True.", "correct": false}]}
{"chain_id": "chain_000001", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11732454", "num_turns": 4, "model": "gpt-4.1", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11732454, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:03 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.**\n\nThe paper (PMCID PMC11732454) reports that HLA-A*31:03 was found more frequently in controls than in patients with Stevens-Johnson Syndrome (SJS), and Table 5 shows an odds ratio (OR) of 0.19 (95% CI: 0.13\u20130.27) for SJS, indicating a decreased risk. The text also states: \"We found the association between HLA alleles (HLA-A\u221701:02; HLA-A\u221702:01, HLA-A\u221724:02, HLA-A\u221731:03...)\" and AED-induced SCARs, and Table 5 specifically lists HLA-A*31:03 as associated with SJS with a low OR, consistent with a protective effect (decreased likelihood).\n\nTherefore, the claim that HLA-A*31:03 is associated with decreased likelihood of SJS when treated with carbamazepine, lamotrigine, or phenytoin is **supported** by the findings of this paper.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:03 and carbamazepine, lamotrigine, phenytoin in Toxicity (PMCID PMC11732454), what confidence interval was reported?", "answer": "0.13\u20130.27", "response": "For the association of HLA-A*31:03 with Stevens-Johnson Syndrome (a form of toxicity) in patients treated with carbamazepine, lamotrigine, or phenytoin, the reported confidence interval in PMCID PMC11732454 is:\n\n**0.13\u20130.27** (as shown in Table 5: OR = 0.19, 95% CI: 0.13\u20130.27).", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000002", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4640545", "num_turns": 4, "model": "gpt-4.1", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4640545, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.\n\nThe paper reports that for the EPHX1 c.337T>C SNP, carriers of the CC genotype showed significantly lower dose-adjusted plasma carbamazepine levels (CDRCBZ) compared to TT carriers (0.76\u00b10.16 vs 0.94\u00b10.49 \u03bcg/mL per mg/Kg; P<0.05), indicating an association between the CC genotype and altered carbamazepine metabolism. Therefore, the claim that genotype CC is not associated with metabolism of carbamazepine compared to CT + TT is contradicted by the findings.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2298771 and carbamazepine in Disease:Epilepsy (PMCID PMC4640545), what p-value was reported for this association?", "answer": "> 0.05", "response": "For the association between rs2298771 (SCN1A c.3184A>G) and carbamazepine in Disease:Epilepsy, the reported p-value in PMCID PMC4640545 is **not significant**. Specifically, Table 3 shows p-values of 0.96 (AG vs AA), 0.85 (GG vs AA), and 0.97 (AG+GG vs AA) for the association with drug resistance, and Table 2/Results text state no significant association with pharmacokinetics. Thus, the reported p-value for this association is **0.96**.", "correct": true}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000003", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4177494", "num_turns": 4, "model": "gpt-4.1", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4177494, is the following pharmacogenomic claim supported or contradicted: Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.**\n\nThe paper (PMCID PMC4177494) reports that carriage of the rs8099917 G allele (i.e., genotypes TG or GG) is significantly associated with a decreased response to pegylated interferon alfa-2a or alfa-2b plus ribavirin in people with Hepatitis C (genotype 1), compared to the TT genotype. Specifically, the presence of the G allele was the best predictor of null-response (OR = 7.9, 95% CI: 1.99-31.18), and patients with the TT genotype had a significantly greater reduction in HCV RNA during treatment. Thus, the claim is **supported**.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs8099917 and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin in Disease:Hepatitis C virus infection (PMCID PMC4177494), what OR was reported?", "answer": "7.9", "response": "The reported odds ratio (OR) for the association of the rs8099917 G allele with null-response to peginterferon alfa-2a, peginterferon alfa-2b, and ribavirin in Hepatitis C virus infection was **7.9** (95% CI: 1.99\u201331.18).", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "true", "correct": true}]}
{"chain_id": "chain_000004", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC7351433", "num_turns": 4, "model": "gpt-4.1", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC7351433, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "supported\n\n**Explanation:**  \nThe paper investigated the association between MTHFR rs1801133 (C677T) genotypes and plasma methotrexate (MTX) levels in pediatric ALL (Precursor Cell Lymphoblastic Leukemia-Lymphoma). The results showed that the TT genotype (homozygous for the T allele) was associated with higher MTX plasma levels compared to the CC genotype, and the CT genotype was not significantly associated. There is no mention of a G allele at this SNP (the alleles are C and T), but if the claim refers to another SNP with G and T alleles, the paper also examined SLC19A1 rs1051266 (G80A, alleles G and A), and found no significant association between the G allele and MTX plasma levels.\n\nTherefore, the claim that \"Allele G is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T\" is **supported** by the findings of this paper.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1801131 and methotrexate in Other:Acute lymphoblastic leukemia (PMCID PMC7351433), what p-value was reported for this association?", "answer": "> 0.05", "response": "For the association between rs1801131 (MTHFR A1298C) and methotrexate plasma levels in pediatric acute lymphoblastic leukemia (ALL), **no statistically significant association was reported** in PMCID PMC7351433. The p-value for this association was **not significant (P > 0.05)**. The exact p-value is not specified in the text, but it is clearly stated that the association was not statistically significant.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "false", "correct": true}]}
{"chain_id": "chain_000005", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3909071", "num_turns": 4, "model": "gpt-4.1", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3909071, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.\n\nThe paper reports that the T allele of rs274618 (and similarly, the T allele of rs274622) is significantly associated with an increased risk of heroin dependence compared to the major allele (which is C for rs274622). Specifically, the T allele is over-represented in heroin addicts and confers a higher odds ratio for heroin dependence. Thus, the claim is supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs13242038 and heroin in Other (PMCID PMC3909071)?", "answer": 619, "response": "619 controls were included in the study of rs13242038 and heroin in Other (PMCID PMC3909071).", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000006", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5519037", "num_turns": 4, "model": "gpt-4.1", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5519037, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Contradicted.**\n\nThe paper reports that carriers of the CYP3A4 rs35599367 variant (CYP3A4*22 allele, i.e., genotype CT) had significantly higher everolimus blood concentrations compared to wild type (CC) patients (P = 0.019). Therefore, genotypes CT + TT are associated with higher concentrations of everolimus compared to genotype CC.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs776746 and everolimus in Disease:Breast Neoplasms (PMCID PMC5519037), what p-value was reported for this association?", "answer": "> 0.05", "response": "For the association between rs776746 (CYP3A5*3) and everolimus concentrations in women with Breast Neoplasms, the paper reports that \"For CYP3A5*1 carriers (n = 4) we found no significantly differences.\" However, a specific p-value is **not reported** in the text for this association.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "false", "correct": true}]}
{"chain_id": "chain_000007", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5207665", "num_turns": 4, "model": "gpt-4.1", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5207665, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to bevacizumab in women with Breast Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "To determine whether the claim \"Allele A is not associated with response to bevacizumab in women with Breast Neoplasms as compared to allele G\" is supported or contradicted by the findings in PMCID PMC5207665, we need to check if any SNPs with alleles A and G were found to be associated with pathologic complete response (pCR) to bevacizumab.\n\nFrom Table 4 and the Results section, several SNPs in angiogenesis-related genes (including ANGPT1, ANGPT2, FGF2, MMP9, TEK, and VEGFA) were found to be associated with pCR (P < 0.05). For example:\n\n- ANGPT2 rs2515462: alleles A/G, AOR 4.31 (1.40\u201313.3), P = 0.011\n- FGF2 rs1960669: alleles T/G, AOR 0.12 (0.02\u20130.79), P = 0.027\n- VEGFA rs833068: alleles A/G, AOR 3.67 (1.16\u201311.60), P = 0.027\n- VEGFA rs833069:", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs17577 and bevacizumab in Disease:Breast Neoplasms (PMCID PMC5207665)?", "answer": 33, "response": "The study in PMCID PMC5207665 does not mention rs17577 specifically in its tables or results. However, if you are referring to the general design for SNP association with bevacizumab response in breast neoplasms, the \"controls\" would be the patients who received chemotherapy alone (i.e., did not receive bevacizumab).\n\nFrom the Methods and Table 1:\n- 34 subjects received bevacizumab in addition to chemotherapy (cases)\n- 29 subjects received chemotherapy alone (controls) and had genotype data available\n\n**Answer:**  \n29 controls were included in the study of SNPs and bevacizumab response in breast neoplasms.  \n(Note: rs17577 is not specifically reported in the paper, but this is the number of controls for the general SNP-bevacizumab association analysis.)", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "false", "correct": false}]}
{"chain_id": "chain_000008", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC1689719", "num_turns": 4, "model": "gpt-4.1", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC1689719, is the following pharmacogenomic claim supported or contradicted: G6PD deficiency is not associated with Hemolysis when treated with trimethoprim. Answer one of: supported, contradicted.", "answer": "supported", "response": "supported\n\nThe paper specifically tested several drugs for their effect on hemolysis in individuals with G6PD deficiency. While sulphamethoxazole (a sulfonamide often combined with trimethoprim) caused hemolysis in some individuals, the paper states: \"Trimethoprim... did not shorten red-cell survival.\" Therefore, the claim that G6PD deficiency is not associated with hemolysis when treated with trimethoprim is supported by the findings of this paper.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "functional_assay", "correct": false}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of G6PD deficiency and trimethoprim in Toxicity (PMCID PMC1689719)?", "answer": 8, "response": "The study included **six** cases (subjects) with G6PD deficiency in the assessment of trimethoprim toxicity. This is stated in the Results section:  \n> \"Trimethoprim (100 mg twice daily for three days) was given to six subjects. There was no evidence of increased haemolysis in any of them.\"", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": false, "response": "false", "correct": true}]}
{"chain_id": "chain_000009", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2850440", "num_turns": 4, "model": "gpt-4.1", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2850440, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with increased risk of Crohn Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.\n\nThe paper reports that for Crohn Disease, SNPs with allele G (e.g., rs17234657 and rs17221417) are associated with an increased risk of Crohn Disease, with statistically significant odds ratios greater than 1 (see Table 1: rs17234657, OR = 1.86, p = 0.0003; rs17221417, OR = 1.46, p = 0.0086). Therefore, the claim that \"Allele G is not associated with increased risk of Crohn Disease\" is contradicted by the findings in this paper.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2542151 (PMCID PMC2850440), what OR was reported?", "answer": "1.0834", "response": "For rs2542151 in the study (PMCID PMC2850440), the reported odds ratio (OR) for Crohn Disease in non-Hispanic European definite cases was **1.08** (95% CI: 0.74\u20131.58), with a p-value of 0.6774.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
